Joinn Laboratories (China) Co Ltd
Company Profile
Business description
Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non-Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.
Contact
A5 Rongjing East Street
Beijing Economic-Technological Development Area
Beijing100176
CHNT: +86 1067869966
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
2,652
Stocks News & Analysis
stocks
Chart of the Week: Opportunities with wide-moat retailers
stocks
New ASX share added to our best ideas
stocks
Fair value downgraded for ASX heavyweight
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,240.30 | 42.60 | 0.46% |
CAC 40 | 8,075.76 | 108.81 | 1.37% |
DAX 40 | 24,449.08 | 335.46 | 1.39% |
Dow JONES (US) | 46,441.10 | 43.21 | 0.09% |
FTSE 100 | 9,453.25 | 6.82 | 0.07% |
HKSE | 27,287.12 | 431.56 | 1.61% |
NASDAQ | 22,755.16 | 95.15 | 0.42% |
Nikkei 225 | 44,936.73 | 385.88 | 0.87% |
NZX 50 Index | 13,451.76 | 17.77 | 0.13% |
S&P 500 | 6,711.20 | 22.74 | 0.34% |
S&P/ASX 200 | 8,945.90 | 40.10 | 0.45% |
SSE Composite Index | 3,882.78 | 20.25 | 0.52% |